246 related articles for article (PubMed ID: 34103484)
1. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.
Gautam N; McMillan JM; Kumar D; Bade AN; Pan Q; Kulkarni TA; Li W; Sillman B; Smith NA; Shetty BLD; Szlachetka A; Edagwa BJ; Gendelman HE; Alnouti Y
Nat Commun; 2021 Jun; 12(1):3453. PubMed ID: 34103484
[TBL] [Abstract][Full Text] [Related]
2. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
3. A year-long extended release nanoformulated cabotegravir prodrug.
Kulkarni TA; Bade AN; Sillman B; Shetty BLD; Wojtkiewicz MS; Gautam N; Hilaire JR; Sravanam S; Szlachetka A; Lamberty BG; Morsey BM; Fox HS; Alnouti Y; McMillan JM; Mosley RL; Meza J; Domanico PL; Yue TY; Moore G; Edagwa BJ; Gendelman HE
Nat Mater; 2020 Aug; 19(8):910-920. PubMed ID: 32341511
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
[TBL] [Abstract][Full Text] [Related]
5. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
Pons-Faudoa FP; Sizovs A; Di Trani N; Paez-Mayorga J; Bruno G; Rhudy J; Manohar M; Gwenden K; Martini C; Chua CYX; Varchi G; Marzinke MA; Grattoni A
J Control Release; 2019 Jul; 306():89-96. PubMed ID: 31136811
[TBL] [Abstract][Full Text] [Related]
6. Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation.
Deodhar S; Sillman B; Bade AN; Avedissian SN; Podany AT; McMillan JM; Gautam N; Hanson B; Dyavar Shetty BL; Szlachetka A; Johnston M; Thurman M; Munt DJ; Dash AK; Markovic M; Dahan A; Alnouti Y; Yazdi A; Kevadiya BD; Byrareddy SN; Cohen SM; Edagwa B; Gendelman HE
Nat Commun; 2022 Jun; 13(1):3226. PubMed ID: 35680875
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
[TBL] [Abstract][Full Text] [Related]
8. Creation of a long-acting rilpivirine prodrug nanoformulation.
Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
Blair CS; Li S; Chau G; Cottle L; Richardson P; Marzinke MA; Eshleman SH; Adeyeye A; Rinehart AR; Margolis D; McCauley M; Hendrix CW; Landovitz RJ;
J Acquir Immune Defic Syndr; 2020 Sep; 85(1):93-97. PubMed ID: 32452972
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Eshleman SH; Fogel JM; Piwowar-Manning E; Chau G; Cummings V; Agyei Y; Richardson P; Sullivan P; Haines CD; Bushman LR; Petropoulos C; Persaud D; Kofron R; Hendrix CW; Anderson PL; Farrior J; Mellors J; Adeyeye A; Rinehart A; St Clair M; Ford S; Rooney JF; Mathew CA; Hunidzarira P; Spooner E; Mpendo J; Nair G; Cohen MS; Hughes JP; Hosseinipour M; Hanscom B; Delany-Moretlwe S; Marzinke MA
J Infect Dis; 2022 May; 225(10):1741-1749. PubMed ID: 35301540
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.
Ibrahim IM; Bade AN; Lin Z; Soni D; Wojtkiewicz M; Dyavar Shetty BL; Gautam N; McMillan JM; Alnouti Y; Edagwa BJ; Gendelman HE
Int J Nanomedicine; 2019; 14():6231-6247. PubMed ID: 31496683
[TBL] [Abstract][Full Text] [Related]
13. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
Blair HA
Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
[TBL] [Abstract][Full Text] [Related]
14. Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures.
Dobard C; Makarova N; Nishiura K; Dinh C; Holder A; Sterling M; Lipscomb J; Mitchell J; Deyounks F; Garber D; Khalil G; Spreen W; Heneine W; García-Lerma JG
J Infect Dis; 2020 Jul; 222(3):391-395. PubMed ID: 32128569
[TBL] [Abstract][Full Text] [Related]
15. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Marzinke MA; Grinsztejn B; Fogel JM; Piwowar-Manning E; Li M; Weng L; McCauley M; Cummings V; Ahmed S; Haines CD; Bushman LR; Petropoulos C; Persaud D; Adeyeye A; Kofron R; Rinehart A; St Clair M; Rooney JF; Pryluka D; Coelho L; Gaur A; Middelkoop K; Phanuphak N; Cohen MS; Hendrix CW; Anderson P; Hanscom B; Donnell D; Landovitz RJ; Eshleman SH
J Infect Dis; 2021 Nov; 224(9):1581-1592. PubMed ID: 33740057
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
[TBL] [Abstract][Full Text] [Related]
19. Rod-like cellulose nanocrystal/cis-aconityl-doxorubicin prodrug: A fluorescence-visible drug delivery system with enhanced cellular uptake and intracellular drug controlled release.
Li N; Lu W; Yu J; Xiao Y; Liu S; Gan L; Huang J
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():179-189. PubMed ID: 30033244
[TBL] [Abstract][Full Text] [Related]
20. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
Ford SL; Lou Y; Lewis N; Kostapanos M; D'Amico R; Spreen W; Patel P
Antivir Ther; 2019; 24(4):301-308. PubMed ID: 30896438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
